Press release

Learning to Sleep announces the outcome of the exercise of warrants of series TO1

Learning 2 Sleep L2S AB (“Learning to Sleep” or “the Company”) today announces the outcome of the exercise of warrants of series TO1 (the “Warrants”) that were included in the units issued in connection with the admission to trading of the Company's shares in February 2022. A total of 200,311 shares were subscribed for with the support of the Warrants, implying a utilization rate of approximately 21.3 percent. Learning to Sleep will receive approximately SEK 0.2 million before issue costs.

The number of outstanding Warrants amounted to 941,520. One (1) Warrant entitled to subscribe for one (1) new share in Learning to Sleep at a subscription price of SEK 1.01 per share, which corresponds to 70 percent of the volume-weighted average price of the Company's share of Nasdaq First North Growth Market calculated for a period of ten (10) trading days before the first day of subscription. The exercise period for the Warrants lasted from 1 June 2022 to 15 June 2022. The final outcome shows that the exercise rate was approximately 21.3 percent, corresponding to 200,311 Warrants for subscription of the same number of shares. Exercised Warrants are replaced by interim shares pending registration with the Swedish Companies Registration Office.
Through the exercise of the Warrants, the total number of shares in Learning to Sleep increases by 200,311, from 12,092,058 to 12,292,369. The share capital in Learning to Sleep increases by SEK 12,018.66, from SEK 725,523.48 to 737,542.14 SEK.
Advisor
Eminova Partners AB acts as financial advisor and Eversheds Sutherland Advokatbyrå AB acts as legal advisor in connection with the redemption of the Warrants. Eminova Fondkommission AB acts as an issuer.

About Us

Learning to Sleep is a digital care provider specializing in the treatment of chronic sleep disorders. The treatment is a combination of a structured treatment program in a mobile application and weekly digital meetings with a psychologist. The company's treatment is based on the latest research in the field and is very successful - over 90 percent of the patients treated receive improved sleep. Sweden is the company's main market and the treatment is reimbuserd by public health care.
For more information see www.learningtosleep.co.uk
The company's Certified Adviser is Eminova Fondkomission AB | +468 684 211 10 | adviser@eminova.se

Important information

Publication, publication or distribution of this press release may in certain jurisdictions be subject to legal restrictions and persons in the jurisdictions in which this press release has been published or distributed should inform themselves of and comply with such legal restrictions. The recipient of this press release is responsible for using this press release and the information herein in accordance with the applicable rules of the respective jurisdiction. This press release does not constitute an offer of, or invitation to, acquire or subscribe for any securities of L2S in any jurisdiction, either from L2S or from anyone else.

This press release neither identifies nor pretends to identify risks (direct or indirect) that may be attributable to an investment in new shares. An investment decision in connection with the New Issue shall be made on the basis of all publicly available information regarding L2S and L2S's shares. The information in this press release is published only as background information and does not claim to be complete. Thus, an investor should not rely solely on the information contained in this press release or its accuracy or completeness.

This press release does not constitute a recommendation for any investors' decisions regarding the New Issue. Each investor or potential investor should conduct their own research, analysis and evaluation of the business and the information described in this Communication and all publicly available information. The price and value of the securities may decrease as well as increase. Achieved results do not constitute a guide for future results.

This press release does not constitute an offer or invitation to acquire or subscribe for securities in the United States. The securities referred to herein may not be sold in the United States without registration, or without the application of an exemption from registration, in accordance with the U.S. law in force at any given time. The Securities Act of 1933 ("Securities Act"), and may not be offered or sold in the United States without being registered, exempt from, or in a transaction not covered by the Securities Act registration requirements. There is no intention to register any securities mentioned herein in the United States or to make a public offering in respect of such securities in the United States. The information in this press release may not be published, published, copied, reproduced or distributed, directly or indirectly, in whole or in part, in or to Australia, Hong Kong, Japan, Canada, New Zealand, Singapore, South Africa, the United States or any other jurisdiction where such publication , publication or distribution of this information would be in violation of applicable rules or where such a measure is subject to legal restrictions or would require additional registration or other measures than those that follow from Swedish law. Measures in violation of these instructions may constitute a breach of applicable securities law.

This press release is not a prospectus within the meaning of Regulation (EU) 2017/1129 of the European Parliament and of the Council of 14 June 2017 (the “Prospectus Regulation”) and has not been approved by any regulatory authority in any jurisdiction. L2S has not approved any offer to the public of shares or rights in any Member State of the EEA and no prospectus has been produced or will be produced in connection with the New Issue. In each EEA Member State, this notice is addressed only to "qualified investors" in that Member State as defined in the Prospectus Regulation.

In the United Kingdom, this document, and other material relating to the securities referred to herein, is distributed and directed only to, and an investment or investment activity relating to this document is only available to and will only be used by, "qualified investors" who are ( (i) persons having professional experience in investment activities and falling within the definition of "professional investors" in Article 19 (5) of the UK Financial Services and Markets Act 2000 (Financial Promotion) Order 2005 (the "Order"); or (ii) persons with high net worth referred to in Article 49 (2) (a) - (d) of the Order (all such persons are collectively referred to as "relevant persons"). An investment or investment measure to which this notice relates is only available to relevant persons in the United Kingdom and will only be implemented with relevant persons. Persons who are not relevant persons should not take any action based on this press release, nor should they act or rely on it.

Stay up to date with our newsletter